San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, Kronos Bio is raising $105 Million in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Norbert Bischofberger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kronos Bio

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

To learn more about Kronos Bio, visit http://kronosbio.com/

Contact:
Norbert Bischofberger, President and Chief Executive Officer
212-871-7920
norbert.bischofberger@kronosbio.com
https://www.linkedin.com/in/norbert-bischofberger-06a0a9150/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved